- Home
- SCYX vs PYN Comparison
SCYX vs PYN Comparison
Compare SCYX & PYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- PYN
- Stock Information
- Founded
- SCYX 1999
- PYN 2002
- Country
- SCYX United States
- PYN United States
- Employees
- SCYX N/A
- PYN N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- PYN Investment Managers
- Sector
- SCYX Health Care
- PYN Finance
- Exchange
- SCYX Nasdaq
- PYN Nasdaq
- Market Cap
- SCYX 41.0M
- PYN 34.5M
- IPO Year
- SCYX 2014
- PYN N/A
- Fundamental
- Price
- SCYX $1.09
- PYN $5.78
- Analyst Decision
- SCYX Buy
- PYN
- Analyst Count
- SCYX 1
- PYN 0
- Target Price
- SCYX N/A
- PYN N/A
- AVG Volume (30 Days)
- SCYX 214.8K
- PYN 19.9K
- Earning Date
- SCYX 03-27-2025
- PYN 01-01-0001
- Dividend Yield
- SCYX N/A
- PYN 5.07%
- EPS Growth
- SCYX N/A
- PYN N/A
- EPS
- SCYX N/A
- PYN N/A
- Revenue
- SCYX $8,566,000.00
- PYN N/A
- Revenue This Year
- SCYX N/A
- PYN N/A
- Revenue Next Year
- SCYX $365.06
- PYN N/A
- P/E Ratio
- SCYX N/A
- PYN N/A
- Revenue Growth
- SCYX N/A
- PYN N/A
- 52 Week Low
- SCYX $0.90
- PYN $4.84
- 52 Week High
- SCYX $3.07
- PYN $6.60
- Technical
- Relative Strength Index (RSI)
- SCYX 46.40
- PYN 53.52
- Support Level
- SCYX $1.02
- PYN $5.68
- Resistance Level
- SCYX $1.13
- PYN $5.77
- Average True Range (ATR)
- SCYX 0.07
- PYN 0.04
- MACD
- SCYX 0.00
- PYN 0.01
- Stochastic Oscillator
- SCYX 44.44
- PYN 88.96
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.